BeeWellwithMS: The science and wellbeing podcast for people with MS (PDF, 670KB)
Straukiene, A., and Hughes, S.
MS and Exercise: what are patients thinking? Exploring attitudes to physical activity in 2023 (PDF, 225KB)
Douglas, L., and Kharin, A.
BeeWellwithMS: The science and wellbeing podcast for people with MS (PDF, 670KB)
Straukiene, A., and Hughes, S.
MS and Exercise: what are patients thinking? Exploring attitudes to physical activity in 2023 (PDF, 225KB)
Douglas, L., and Kharin, A.
(FES) Service Increasing student capacity using a different model of clinical education: The benefits and challenges (PDF, 250KB)
Peace, C., and Aldridge, D.
Case Study: Multi-faceted, long-term use of Functional Electrical Stimulation (FES) (PDF, 530KB)
Maycock, L., and Mardon, N.
Diroximel Fumarate in Young Adults With Relapsing-Remitting Multiple Sclerosis: Interim Safety and Efficacy Results From the Phase 3 EVOLVE-MS-1 Study (PDF, 215KB)
Wray, S., Zhu, C., Singer, B.A., et al.
Disease-Modifying Therapy Choice in People With Multiple Sclerosis in the Era of Covid-19: Characterizing Outcomes in Patients Who Switched From Anti-CD20 Therapies to Diroximel Fumarate (PDF, 190KB)
Kaczmarek, O., Sethi, A., Teng, E., et al.
Do people with multiple sclerosis (MS) and health professionals share perceptions on exercise delivery and support? (PDF, 125KB)
Hensman, M.Y., Veldhuijzen van Zanten, J.J.C.S., Douglas, M. et al.
Efficacy and Safety in Phase 3 EVOLVE-MS-1 After Switching from Glatiramer Acetate or Interferon or Continuing on Diroximel Fumarate (PDF, 219KB)
Wray, S., Bergh, F., Wundes, A., et al.
Flushing and Gastrointestinal Adverse Event Analysis From the Phase 3 EVOLVE-MS-1 Study of Diroximel Fumarate in Patients With Relapsing-Remitting Multiple Sclerosis (PDF, 210KB)
Faissner, S., Antezana, A.O., Hernández Pérez, M.A., et al.
Is there anything you would like to tell us about your experience today? A Content Analysis (PDF, 215KB)
Swain, P., Taylor, L., Morris, H. et al.
Joined up thinking, setting up a Multiple Sclerosis / Urology Service (PDF, 330KB)
Rice, L., and Reid.
MS cognition clinic handbook - Karger Fast Facts: Cognition in Multiple Sclerosis (PDF, 465KB)
Langdon, D., and Young, C.
Peer Connect: A Feasibility RCT of Peer Coaching for Adults with Long-term Conditions (PDF, 290KB)
Dennett, R., Straukiene, A., Thompson, T. et al.
Real own experience of Kesimpta (Ofatumumab) across the Thames Valley Hospitals (PDF, 295KB)
Wyatt, S.
Recognising Quality in the Delivery of Services in Multiple Sclerosis (PDF, 430KB)
QuDoS
Refuel-MS: Developing, optimising, and implementing a blended digital self-management treatment for fatigue in multiple sclerosis (PDF, 400KB)
Moss-Morris, R., Freeman, J., Hendrie, W., et al.
Safety and Clinical Efficacy Outcomes from the Long-Term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results (PDF, 70KB)
Oh, J., Syed, S. , Orogun, L., et al.